Scynexis (SCYX) Cash & Current Investments (2013 - 2026)
Scynexis' (SCYX) quarterly Cash & Current Investments came in at $36.8 million in Q1 2026, down 32.24% YoY from $54.2 million in Q1 2025, and up 72.22% on a QoQ basis from $21.3 million in Q4 2025.
Scynexis (SCYX) Cash & Current Investments (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 14 years of Cash & Current Investments data on file, last reported at $36.8 million in Q1 2026.
- Quarterly Cash & Current Investments fell 32.24% year-over-year to $36.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.8 million (down 32.24% YoY) and the FY2025 annual result came in at $21.3 million, up 29.44% from the prior year.
- Cash & Current Investments grew to $36.8 million in Q1 2026, from $21.3 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $130.7 million in Q2 2024 to a low of $16.5 million in Q4 2024.
- A 5-year average of $59.8 million and a median of $44.8 million in 2025 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2023 — Cash & Current Investments surged 53.74% — and 2024, when it slumped 72.38%.
- Tracing SCYX's Cash & Current Investments over 5 years: stood at $73.5 million in 2022, then sank by 53.16% to $34.4 million in 2023, then tumbled by 52.12% to $16.5 million in 2024, then increased by 29.44% to $21.3 million in 2025, then soared by 72.22% to $36.8 million in 2026.
- The last three Cash & Current Investments figures came in at $36.8 million (Q1 2026), $21.3 million (Q4 2025), and $38.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Scynexis | 62.02 Mn | -52.68 Mn | - | 114.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 114.70 Mn |
| Mar 31, 2026 | 36.75 Mn |
| Dec 31, 2025 | 21.34 Mn |
| Sep 30, 2025 | 37.98 Mn |
| Jun 30, 2025 | 44.79 Mn |
| Mar 31, 2025 | 54.24 Mn |
| Dec 31, 2024 | 16.49 Mn |
| Sep 30, 2024 | 29.17 Mn |
| Jun 30, 2024 | 130.74 Mn |
| Mar 31, 2024 | 35.86 Mn |
| Dec 31, 2023 | 34.43 Mn |
| Sep 30, 2023 | 105.58 Mn |
| Jun 30, 2023 | 85.54 Mn |
| Mar 31, 2023 | 26.97 Mn |
| Dec 31, 2022 | 73.50 Mn |
| Sep 30, 2022 | 68.68 Mn |
| Jun 30, 2022 | 118.70 Mn |
| Mar 31, 2022 | 95.21 Mn |
| Dec 31, 2021 | 104.48 Mn |
| Sep 30, 2021 | 100.11 Mn |